A therapeutic review document provides a rapid collation of published literature evidence to support DTC decision making. It provides a critical evaluation of the literature but does not make recommendations about place in therapy of the medicine in question. It can be produced much more quickly than a position statement, and is therefore of value to DTCs in managing formulary decisions.
Adalimumab in inflammatory bowel disorders
Antiplatelet Therapies: Current Issues
November 2009 (update)
Drugs for the treatment of secondary hyperparathyroidism and hyperphosphataemia
Infliximab in Crohn's Disease
Infliximab in Ulcerative Colitis
Intravenous bisphosphonates in osteoporosis: Key Questions